HomeUSMLE Step 1Pharmacology

Master Pharmacology
for USMLE Step 1

Access 30+ high-yield questions tailored for the 2026 syllabus. Includes AI-powered explanations and performance tracking.

Start Free Practice View Full Syllabus
HIGH YIELD NOTES ~5 min read

Core Concepts

Pharmacology for USMLE Step 1 covers drug-body interactions.

  • Pharmacokinetics (ADME):
    • Absorption: Bioavailability (F), first-pass metabolism.
    • Distribution: Volume of Distribution (Vd = Dose/Cp). High Vd for lipid-soluble drugs. Protein binding reduces free drug.
    • Metabolism: Liver (CYP450, Phase I/II). Prodrugs require activation.
    • Excretion: Kidney. Clearance (Cl). Half-life (t1/2). Steady state ~4-5 t1/2.
    • Kinetics: First-order (constant fraction, most drugs) vs. Zero-order (constant amount, e.g., alcohol, phenytoin).
  • Pharmacodynamics:
    • Receptors: Ligand-gated, G-protein, enzyme-linked, intracellular.
    • Agonists/Antagonists: Agonist (activates), Antagonist (blocks). Competitive vs. Non-competitive.
    • Dose-Response: Potency (left shift, less drug for effect) vs. Efficacy (max effect, higher curve).
    • Therapeutic Index (TI): TD50/ED50. High TI = safer.
    • Tolerance/Tachyphylaxis: Decreased drug response over time.
  • Drug Interactions: PK (ADME alteration, e.g., CYP450 inducers/inhibitors) or PD (additive, synergistic, antagonistic).
  • Adverse Drug Reactions (ADRs):
    • Type A: Dose-dependent, predictable.
    • Type B: Dose-independent, unpredictable (allergic, idiosyncratic).
    • Teratogenicity: Fetal harm (e.g., ACEi, Warfarin, Isotretinoin).

Clinical Presentation

  • Therapeutic Effects: Manifestations of desired drug action (e.g., lowered BP, pain relief).
  • Common Side Effects: Predictable from MOA.
    • Anticholinergic: Dry mouth, blurred vision, urinary retention, constipation, confusion.
    • Adrenergic: Tachycardia, tremors, anxiety.
    • CNS: Sedation/excitation, dizziness.
    • GI: Nausea, vomiting, diarrhea.
  • Drug Toxicity: Exaggerated effects or organ damage (e.g., hepatotoxicity, nephrotoxicity).
  • Allergic Reactions: Rash, urticaria, anaphylaxis.

Diagnosis (Gold Standard)

Assessing drug effect, toxicity, or interaction.

  • Therapeutic Drug Monitoring (TDM): Measuring plasma drug concentrations for narrow therapeutic index drugs (e.g., Lithium, Digoxin, Phenytoin, Aminoglycosides, Vancomycin).
  • Clinical Assessment: Comprehensive history (meds, OTCs), physical exam, symptom evaluation.
  • Laboratory & Imaging: Organ function tests (LFTs, BUN/Cr), ECG.
  • Dechallenge/Rechallenge: Confirming drug role in adverse events.

Management (First Line)

Managing drug-related issues.

  • Dose Adjustment: Titrate based on efficacy, side effects, patient factors (renal/hepatic function, age).
  • Switch Medications: For intolerable side effects or therapeutic failure.
  • Supportive Care: Symptom management.
  • Specific Antidotes: Reversing overdose/toxicity (e.g., Naloxone for opioids, Flumazenil for benzodiazepines, Acetylcysteine for acetaminophen).
  • Discontinuation: For severe/life-threatening ADRs.
  • Patient Education: Crucial for adherence, side effect recognition.

Exam Red Flags

  • Narrow Therapeutic Index Drugs: TDM, toxicity, interactions (Warfarin, Lithium, Digoxin, Phenytoin, Theophylline).
  • CYP450 Interactions: Inducers (Rifampin, Phenytoin, Carbamazepine); Inhibitors (Grapefruit juice, Macrolides, Azoles, Ritonavir).
  • Organ-Specific Toxicities:
    • Hepatotoxicity: Acetaminophen (OD), Isoniazid, Statins, Valproic acid.
    • Nephrotoxicity: Aminoglycosides, NSAIDs, ACE inhibitors, Amphotericin B, Vancomycin.
    • Ototoxicity: Aminoglycosides, Loop diuretics, Cisplatin.
    • Cardiotoxicity: Doxorubicin (dilated CM), Amiodarone, TCAs (QT).
    • Pulmonary Fibrosis: Amiodarone, Bleomycin, Methotrexate.
    • Myelosuppression: Chemo, Chloramphenicol, Methotrexate.
  • Teratogenic Drugs (Pregnancy Contraindications): ACEi/ARBs, Warfarin, Isotretinoin, Methotrexate, Phenytoin, Valproic acid, Tetracyclines, Lithium, Thalidomide.
  • Key Antidotes: Naloxone (opioids), Flumazenil (benzos), N-acetylcysteine (acetaminophen), Protamine (heparin), Vit K (warfarin), Fomepizole (methanol/ethylene glycol).
  • MAO Inhibitors: Hypertensive Crisis (tyramine foods), Serotonin Syndrome (SSRIs, SNRIs).

Sample Practice Questions

Question 1

A 68-year-old male presents to the emergency department with sudden onset shortness of breath and pleuritic chest pain. A CT pulmonary angiography reveals multiple bilateral pulmonary emboli. He is started on intravenous unfractionated heparin and warfarin. Which of the following best describes the mechanism of action of warfarin?

A) Potentiates the activity of antithrombin III.
B) Binds to thrombin, preventing its activation.
C) Inhibits vitamin K epoxide reductase.
D) Directly inhibits Factor Xa.
Explanation: This area is hidden for preview users.
Question 2

A 72-year-old woman with metastatic breast cancer receiving palliative care reports severe constipation, straining during bowel movements, and abdominal discomfort for the past week. Her current medications include sustained-release morphine 60 mg twice daily, paracetamol 1g three times daily, and metoclopramide 10 mg three times daily for nausea. She has no history of bowel obstruction. What is the most appropriate initial pharmacological intervention for her constipation?

A) Administer loperamide
B) Increase the dose of metoclopramide
C) Initiate naloxone
D) Prescribe polyethylene glycol
Explanation: This area is hidden for preview users.
Question 3

A 70-year-old male with a 10-year history of Parkinson's disease has been managed with carbidopa/levodopa. Over the past year, he has started experiencing unpredictable fluctuations in motor function, characterized by periods of good mobility ('on' periods) followed by sudden rigidity and bradykinesia ('off' periods). Additionally, he has developed involuntary, writhing movements of his limbs and trunk. These motor complications are most likely related to which of the following?

A) Development of drug-induced parkinsonism
B) Progressive disease severity and chronic levodopa therapy
C) Serotonin syndrome
D) Acute dystonic reaction
Explanation: This area is hidden for preview users.

Ready to see the answers?

Unlock All Answers

USMLE Step 1

  • ✓ 30+ Pharmacology Questions
  • ✓ AI Tutor Assistance
  • ✓ Detailed Explanations
  • ✓ Performance Analytics
Get Full Access